Companies that are decreasing efficiency in utilisation of Shareholders funds ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

albigula health and neither fecal nor urinary oxalate levels increased significantly 4. During the diet trial, animals were placed in metabolic cages to separate urine and feces into sterile 50-ml ...

Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.

Karen L. Hassenplug, Pharm.D.; Jill S. Burkiewicz, Pharm.D., BCPS; Terri L. Jackson, Ph.D., B.S.Pharm.; Laura R. Peppers, Pharm.D., BCPS Identifying baseline ...

No other corporate actions details are available.

An­thos Ther­a­peu­tics’ an­ti­co­ag­u­lant pos­es a low­er risk of bleed­ing events than Bay­er and J&J’s Xarel­to when used to pre­vent blood clots in atri­al fib­ril­la ...

The anticoagulants apixaban and dabigatran do not cause more bleeding than aspirin when treating stroke or atrial fibrillation, according to an analysis of randomized clinical trials published in ...

11 in the Annals of Internal Medicine. Michael Ke Wang, M.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues estimated the differences in bleeding risks between therapeutic-dose ...